Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...